Treating Impaired Cognition in Schizophrenia

Research output: Contribution to journalReview article

32 Scopus citations

Abstract

Cognitive impairment is a core feature of schizophrenia that substantially accounts for poor functional outcomes associated with this disease in areas such as work, independent living and social relationships. Until recently, drug development in schizophrenia has focused on developing compounds that mainly target the positive psychotic symptoms of the illness. Although current antipsychotic drugs treat psychosis in schizophrenia rather well, their impact on cognitive dysfunction is minimal. In recent years there has been growing interest in developing novel treatments for cognitive deficits in schizophrenia. In this review we discuss pharmacologic strategies considered most likely to improve cognition. These putative molecular targets include receptors for acetylcholine, dopamine, glutamate, g-aminobutyric acid (GABA), serotonin and histamine. In addition, we propose that not only pharmacological, but also psychological treatments should be considered to enhance cognition in schizophrenia.

Original languageEnglish (US)
Pages (from-to)1587-1594
Number of pages8
JournalCurrent Pharmaceutical Biotechnology
Volume13
Issue number8
DOIs
StatePublished - Jun 1 2012

Keywords

  • Acetylcholine
  • Cognition
  • Cognitive remediation
  • Dopamine
  • GABA
  • Glutamate
  • Histamine
  • Serotonin

ASJC Scopus subject areas

  • Biotechnology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Treating Impaired Cognition in Schizophrenia'. Together they form a unique fingerprint.

  • Cite this